Published Friday in JAMA, scientists recently explored a risk-based mammography tactic that tailors regular imaging regimens to each individual’s danger of developing the disease. 

Alleged transgressions took place between February and August, including the FDA rejecting Telix’s application for a new brain cancer imaging agent. 

DECT systems allow for a contrast dose reduction of up to 25% during computed tomography pulmonary angiography exams.